DEF: Theriva Biologics Seeks Shareholder Vote on Warrant Issuance

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on February 11, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Summary

• A Special Meeting of Stockholders is scheduled for February 11, 2026, at 3:30 p.m. (local time) in Barcelona, Spain.
• The primary proposal (Warrant Exercise Proposal) seeks stockholder approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of new warrants.
• These new warrants were issued to institutional investors as an inducement for them to exercise existing warrants in a private placement that closed on October 17, 2025.
• The exercise price for the new warrants is $0.54 per share.
• Approval of this proposal is a condition for the company to receive up to approximately $8.7 million in gross proceeds from the cash exercise of these new warrants.
• The second proposal (Adjournment Proposal) seeks authorization to adjourn the meeting if there are insufficient votes for the Warrant Exercise Proposal or to establish a quorum.
• The Board of Directors unanimously recommends a 'FOR' vote for both proposals.
• A previous special meeting on December 15, 2025, to seek this approval failed to convene due to a lack of quorum.

Sentiment

Score: 6

Explanation: The filing addresses a necessary corporate action to finalize a capital raise mechanism. While the potential for $8.7 million is positive for funding, the significant dilution and the prior failure to achieve a quorum introduce elements of uncertainty and operational challenge. The need for approval for a transaction already completed (the inducement agreement) and the potential for further delays if approval is not met are minor negatives. The overall sentiment is neutral to slightly positive, as it's a procedural step to secure funding.

Positives

• Approval of the Warrant Exercise Proposal could lead to approximately $8.7 million in gross proceeds for the company, which is crucial for funding operations.
• The inducement agreement successfully prompted institutional investors to exercise existing warrants for cash at a reduced price of $0.54 per share, generating immediate capital.

Negatives

• Failure to approve the Warrant Exercise Proposal means the company cannot permit the exercise of the new warrants, foregoing up to approximately $8.7 million in potential gross proceeds.
• If the Warrant Exercise Proposal is not approved, the company will incur substantial additional costs and expenses by being required to hold subsequent stockholder meetings every 60 days until approval is obtained or the warrants expire.
• Approval of the Warrant Exercise Proposal will result in significant dilution for existing stockholders upon the issuance of 16,184,560 additional shares.
• The potential sale of these 16,184,560 shares into the public market could materially and adversely affect the market price of the common stock.
• The exercise price of $0.54 for the new warrants is below the closing price of $0.84 on October 15, 2025, triggering NYSE American stockholder approval requirements.

Risks

• Failure to obtain stockholder approval for the Warrant Exercise Proposal could adversely impact the company's ability to fund its operations due to the loss of up to $8.7 million in potential funds.
• The issuance of 16,184,560 additional shares upon warrant exercise will dilute existing stockholders' ownership interests.
• The subsequent sale of these newly issued shares into the public market could negatively affect the market price of the company's common stock.
• The company is obligated to call additional stockholder meetings every 60 days if approval is not obtained, incurring further costs and expenses.

Future Outlook

The company anticipates receiving up to approximately $8.7 million in gross proceeds if stockholders approve the Warrant Exercise Proposal and all new warrants are exercised for cash. Failure to obtain this approval would prevent the company from realizing these funds and would necessitate holding additional stockholder meetings every 60 days, incurring further expenses, until approval is secured or the warrants are no longer outstanding.

Management Comments

• Your vote is very important. Whether or not you plan to attend the Special Meeting, we encourage you to read the accompanying Proxy Statement and to submit your proxy or voting instructions as soon as possible.
• In order to ensure the representation of a quorum at the Special Meeting, stockholders who do not expect to attend the Special Meeting are urged to vote as soon as possible.
• The Board believes that if at the Special Meeting, the number of votes represented by shares of our Common Stock, present or represented and voting in favor of the Warrant Exercise Proposal, is insufficient to approve the Warrant Exercise Proposal or establish a quorum, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional votes to approve the Warrant Exercise Proposal.

Industry Context

This filing primarily concerns a specific corporate finance action (warrant issuance and stockholder approval) and compliance with NYSE American listing rules. It does not provide broader industry context or trends, focusing instead on the company's internal capital structure and governance requirements.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for significant dilution (16,184,560 additional shares, approximately 45% of current outstanding shares) if the Warrant Exercise Proposal is approved and warrants are exercised. The market price of common stock could be adversely affected by the sale of these shares. Failure to approve could lead to the company missing out on up to $8.7 million in funding.
• **Company Operations**: The potential $8.7 million in gross proceeds from warrant exercises is crucial for funding operations. Failure to secure these funds could adversely impact the company's financial health and operational capabilities.
• **Institutional Investors (Warrant Holders)**: Their new warrants are exercisable only upon stockholder approval. Their investment strategy and potential returns are directly tied to this vote.

Next Steps

• Hold a Special Meeting of Stockholders on February 11, 2026, to vote on the Warrant Exercise Proposal and the Adjournment Proposal.
• If the Warrant Exercise Proposal is approved, the new warrants will become exercisable, potentially leading to the issuance of 16,184,560 shares and up to $8.7 million in proceeds.
• If the Warrant Exercise Proposal is not approved, the company is obligated to call additional stockholder meetings every 60 days until approval is obtained or the new warrants are no longer outstanding.
• Stockholders can submit proposals for the 2026 Annual Meeting by March 11, 2026 (Rule 14a-8) or May 1, 2026 (Bylaws).
• Stockholders intending to solicit proxies for director nominees must provide notice by June 30, 2026.

Key Dates

Recommendation

The filing outlines a necessary procedural step to finalize a previously agreed-upon capital raise mechanism. While the potential for $8.7 million in gross proceeds is a positive for the company's funding, the significant potential dilution of 16,184,560 shares (representing approximately 45% of current outstanding shares) and the potential adverse impact on the market price are considerable concerns for existing shareholders. The prior failure to achieve a quorum for this same proposal indicates some shareholder apathy or resistance. Investors should hold to see the outcome of the vote and assess the subsequent impact on share price and company funding, as the immediate impact is largely procedural, but the long-term implications of dilution are significant.

Keywords

Theriva Biologics, TOVX, Warrant Exercise, Private Placement, Stockholder Meeting, Proxy Statement, Share Dilution, Capital Raise, NYSE American, Corporate Governance